Gilead Sciences Inc. said that its Quad regimen for treating HIV infection met its primary objective in a Phase II study, fueling hopes that the combination pill could diversify the company's pipeline as its blockbuster HIV drugs face a looming patent cliff. (BioWorld Today)

PTC Therapeutics Inc. has completed a $50 million financing, the proceeds for which will be used to prepare for the anticipated launch of the drug in Duchenne's muscular dystrophy in the first half of 2011. (BioWorld Today)